Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Offers up to $470K in Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Canadian diagnostics developer Miraculins aims to gain up to C$500,500 ($469,200) in gross proceeds through a private placement of as many as 7,150,000 units priced at C$.07 per unit.

The firm, which trades on the TSX Venture Exchange, said on Tuesday that it plans to use the proceeds from the placement for research and development and for corporate working capital.

The units in the placement will include one common share and one share purchase warrant, priced at C$.10. The warrants will be callable by the company if the share price rises above C$.14 for any 20 out of 30 consecutive trading days.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.